Acorda Therapeutics (Acorda Therapeutics) Cash per Share : $24.14 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Acorda Therapeutics Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Acorda Therapeutics's Cash per Share for the quarter that ended in Dec. 2023 was $24.14.

Acorda Therapeutics Cash per Share Historical Data

The historical data trend for Acorda Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics Cash per Share Chart

Acorda Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash per Share

Get a 7-Day Free Trial

316.57

150.73

68.91

30.85

24.14

Acorda Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash per Share	Get a 7-Day Free Trial															30.85	24.86	20.35	26.14	24.14

Acorda Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Acorda Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	29.979	/	1.2
	=	24.14

Acorda Therapeutics's Cash per Share for the quarter that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	29.979	/	1.2
	=	24.14

Acorda Therapeutics (OTCPK:ACORQ) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Acorda Therapeutics Cash per Share Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Acorda Therapeutics (Acorda Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (OTCPK:ACORQ) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965

Website

https://www.acorda.com

Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.

Executives

Thomas M. Burns	director	2910 SEVENTH STREET, BERKELEY CA 94710
Ron Cohen	officer: CEO and President	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
John Varian	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Michael A Gesser	officer: Chief Financial Officer	420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Neil S. Belloff	officer: General Counsel	11 RADNOR LANE, MAHOPAC NY 10541
Kerry M Clem	officer: Chief Commercial Officer	420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Morales	officer: Interim PAO & PFO	420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Jane Wasman	officer: Exec V Pres, Gen Cnsl & Sec	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella	officer: Exec. VP-Commercial Dvlpmnt	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David Lawrence	officer: Chief Financial Officer	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Capital Management Lp	10 percent owner	152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Lorin Randall	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Burkhard Blank	officer: Chief Medical Officer	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Management, Inc.	10 percent owner	152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Matthew Sirovich	10 percent owner	C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123